These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38577056)

  • 1. A case of dupilumab-induced psoriasis-like eruption treated with baricitinib.
    Kinoshita Y; Imanishi H; Oshimo T; Tsuruta D
    Skin Health Dis; 2024 Apr; 4(2):e338. PubMed ID: 38577056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective.
    Johansson E; Giovannitti M; Mezzetti M; Lu N; Sabatino S
    J Med Econ; 2023; 26(1):1155-1166. PubMed ID: 37674383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study.
    Liu B; Song X; Liao S; Luan T; Zhao Z
    Int Arch Allergy Immunol; 2023; 184(10):966-974. PubMed ID: 37245505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience of baricitinib in atopic dermatitis: including add-on therapy for patients using dupilumab.
    Lim JH; Kwon SH; Lew BL
    Int J Dermatol; 2024 Feb; 63(2):196-200. PubMed ID: 38058206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Clinical and histopathological characteristics of psoriasiform erythema and
    Ali K; Wu L; Qiu Y; Li M
    Front Med (Lausanne); 2022; 9():932766. PubMed ID: 35966849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pustular Psoriasis in a Patient Treated with Dupilumab for Atopic Dermatitis: A Case Report.
    Liu L; Chen J; Tang K; Li F; Li S; Ding X
    Clin Cosmet Investig Dermatol; 2023; 16():2217-2221. PubMed ID: 37601418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis.
    Jia X; Li C; Wu J; Liu Q
    J Drugs Dermatol; 2022 Mar; 21(3):311-312. PubMed ID: 35254760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis.
    de Bruin-Weller MS; Serra-Baldrich E; Barbarot S; Grond S; Schuster C; Petto H; Capron JP; Raibouaa A; Werfel T
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1481-1491. PubMed ID: 35543919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab for the treatment of adolescents with atopic dermatitis.
    Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
    Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study.
    Napolitano M; Fabbrocini G; Patruno C
    J Dermatol; 2023 Jul; 50(7):880-887. PubMed ID: 36914982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Sun X; Chen Z; Akinlade B; Boklage S; Guillemin I; Kosloski MP; Kamal MA; O'Malley JT; Patel N; Graham NMH; Bansal A
    Br J Dermatol; 2021 May; 184(5):857-870. PubMed ID: 32969489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis.
    Weiss L; Marbet CP; Branca LB; Mühleisen B; Navarini A
    Case Rep Dermatol; 2024; 16(1):144-148. PubMed ID: 39015397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.